search
Back to results

Dose-escalation, Repeated and Single Oral Dosing Study

Primary Purpose

Acute Coronary Syndrome

Status
Terminated
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
APD791
Clopidogrel
Aspirin
Placebo for APD791
Sponsored by
IlDong Pharmaceutical Co Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Acute Coronary Syndrome

Eligibility Criteria

20 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. a healthy adult between 20 and 45 years old at the time of visit for screening
  2. a person who is able to give written consent
  3. a person between 50 and 85 kg at the time of visit for screening
  4. a woman who is negative on a serum hCG test at the time of visit and the day before a trial, and who is not nursing, a woman who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, or who had a contraceptive operation no later than 120 days before visit for screening, or who is menopausal, a man who had a contraceptive operation no later than 120 days before visit for screening, or who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, and also agree not to donate sperm
  5. a person more than hemoglobin 12 g/dL at the time of screening (a woman more than hemoglobin 11 g/dL)
  6. a person whose vital signs were in the normal range at the time of visit for screening, or who is medically determined not to be clinically significant by an investigator

Exclusion Criteria:

  1. a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer within 90 days from the time of visit for screening
  2. a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease, ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or herniotomy) affecting the absorption of a clinical trial drug
  3. a person with the medical history of blood coagulation disorder or hemorrhagic diseases, or with clinically significant abnormal findings decided by a investigator on blood coagulation test at the time of screening
  4. a woman with the medical history of dysfunctional uterine bleeding within a year from the time of visit for screening
  5. a person with the medical history of epilepsy or convulsion
  6. a person with the medical history of internal organ transplant
  7. a person expected to be hard to complete a clinical trial because of surgery or medical procedures planned within a clinical trial period
  8. a person with the medical history of clinically significant new diseases within 30 days from the time of visit for screening according to investigator's decision
  9. a person with hypersensitivity reaction to a drug or gelatin, or the medical history of clinically significant hypersensitivity reaction
  10. a person with the history of drug abuse, or with a positive reaction to a drug possible to be abused on urine drug screening
  11. a person with the medical history of alcohol abuse within two years from the time of visit for screening
  12. a person who is a smoker, or with a positive reaction on a urine nicotine test conducted at the time of visit for screening
  13. a person who donated whole blood within 60 days or constituents of blood within 30 days, or received a blood transfusion within 30 days from the time of visit for screening
  14. a person taking other clinical trial drugs within 90 days from the time of visit for screening
  15. a person taking a prescription drug within 30 days, or a contraindicated drug or oriental medicine within 14 days from the time of visit for screening
  16. a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test, HIV test, syphilis test)
  17. a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or creatinine more than 1.25 times of the reference upper limit(UNL)
  18. a person expected to be hard to complete a clinical trial due to physical or mental status according to investigator's medical decision at the time of visit for screening

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm 6

    Arm 7

    Arm 8

    Arm 9

    Arm 10

    Arm 11

    Arm 12

    Arm 13

    Arm 14

    Arm 15

    Arm 16

    Arm Type

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Placebo Comparator

    Experimental

    Experimental

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    APD791 10mg single dose

    APD791 20mg single dose

    APD791 40mg single dose

    APD791 10mg

    APD791 20mg

    APD791 40mg

    APD791 80mg

    APD791 160mg

    APD791 240mg

    APD791 320mg

    APD791 Placebo

    APD791 2mg MD

    APD791 5mg MD

    APD791 10mg MD

    APD791 20mg MD

    APD791 placebo MD

    Arm Description

    APD791 10mg single dose

    APD791 20mg single dose

    APD791 40mg single dose

    APD791 10mg single dose + Aspirin + Clopidogrel

    APD791 20mg single dose + Aspirin + Clopidogrel

    APD791 40mg single dose + Aspirin + Clopidogrel

    APD791 80mg single dose + Aspirin + Clopidogrel

    APD791 160mg single dose + Aspirin + Clopidogrel

    APD791 240mg single dose + Aspirin + Clopidogrel

    APD791 320mg single dose + Aspirin + Clopidogrel

    APD791 placebo for single dose + Aspirin + Clopidogrel

    APD791 2mg multiple dose + Aspirin + Clopidogrel

    APD791 5mg multiple dose + Aspirin + Clopidogrel

    APD791 10mg multiple dose + Aspirin + Clopidogrel

    APD791 placebo for multiple dose + Aspirin + Clopidogrel

    APD791 placebo for multiple dose + Aspirin + Clopidogrel

    Outcomes

    Primary Outcome Measures

    Pharmacokinetics-Cmax
    Pharmacokinetics-Tmax
    Pharmacodynamics-% inhibition of serotonin-stimulated platelet aggregation
    Pharmacodynamics-change of serotonin-stimulated platelet aggregation
    Pharmacodynamics-% inhibition of TRAP-induced platelet aggregation

    Secondary Outcome Measures

    adverse event monitoring
    physical examination
    vital signs
    ECG
    laboratory test

    Full Information

    First Posted
    January 27, 2015
    Last Updated
    February 11, 2019
    Sponsor
    IlDong Pharmaceutical Co Ltd
    Collaborators
    Asan Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02419820
    Brief Title
    Dose-escalation, Repeated and Single Oral Dosing Study
    Official Title
    Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Temanogrel Co-administered With Aspirin and Clopidogrel
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2019
    Overall Recruitment Status
    Terminated
    Why Stopped
    Sponsor Decision
    Study Start Date
    March 2015 (Actual)
    Primary Completion Date
    April 2016 (Actual)
    Study Completion Date
    April 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    IlDong Pharmaceutical Co Ltd
    Collaborators
    Asan Medical Center

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of APD791 (Temanogrel) Co-administered with Aspirin and Clopidogrel.
    Detailed Description
    To investigate pharmacokinetic and pharmacodynamic characteristics of Temanogrel when orally co-administered with Aspirin and/or Clopidogrel in healthy subject. a person determined to be suitable for the purpose of this clinical trial by investigator with consideration for the age and the health status of a volunteer is selected Assess the safety of Temanogrel when orally co-administered with Aspirin and/or Clopidogrel in healthy subjects.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Acute Coronary Syndrome

    7. Study Design

    Primary Purpose
    Screening
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    104 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    APD791 10mg single dose
    Arm Type
    Experimental
    Arm Description
    APD791 10mg single dose
    Arm Title
    APD791 20mg single dose
    Arm Type
    Experimental
    Arm Description
    APD791 20mg single dose
    Arm Title
    APD791 40mg single dose
    Arm Type
    Experimental
    Arm Description
    APD791 40mg single dose
    Arm Title
    APD791 10mg
    Arm Type
    Experimental
    Arm Description
    APD791 10mg single dose + Aspirin + Clopidogrel
    Arm Title
    APD791 20mg
    Arm Type
    Experimental
    Arm Description
    APD791 20mg single dose + Aspirin + Clopidogrel
    Arm Title
    APD791 40mg
    Arm Type
    Experimental
    Arm Description
    APD791 40mg single dose + Aspirin + Clopidogrel
    Arm Title
    APD791 80mg
    Arm Type
    Experimental
    Arm Description
    APD791 80mg single dose + Aspirin + Clopidogrel
    Arm Title
    APD791 160mg
    Arm Type
    Experimental
    Arm Description
    APD791 160mg single dose + Aspirin + Clopidogrel
    Arm Title
    APD791 240mg
    Arm Type
    Experimental
    Arm Description
    APD791 240mg single dose + Aspirin + Clopidogrel
    Arm Title
    APD791 320mg
    Arm Type
    Experimental
    Arm Description
    APD791 320mg single dose + Aspirin + Clopidogrel
    Arm Title
    APD791 Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    APD791 placebo for single dose + Aspirin + Clopidogrel
    Arm Title
    APD791 2mg MD
    Arm Type
    Experimental
    Arm Description
    APD791 2mg multiple dose + Aspirin + Clopidogrel
    Arm Title
    APD791 5mg MD
    Arm Type
    Experimental
    Arm Description
    APD791 5mg multiple dose + Aspirin + Clopidogrel
    Arm Title
    APD791 10mg MD
    Arm Type
    Experimental
    Arm Description
    APD791 10mg multiple dose + Aspirin + Clopidogrel
    Arm Title
    APD791 20mg MD
    Arm Type
    Experimental
    Arm Description
    APD791 placebo for multiple dose + Aspirin + Clopidogrel
    Arm Title
    APD791 placebo MD
    Arm Type
    Placebo Comparator
    Arm Description
    APD791 placebo for multiple dose + Aspirin + Clopidogrel
    Intervention Type
    Drug
    Intervention Name(s)
    APD791
    Other Intervention Name(s)
    Temanogrel
    Intervention Description
    Temanogrel
    Intervention Type
    Drug
    Intervention Name(s)
    Clopidogrel
    Other Intervention Name(s)
    Plavix
    Intervention Description
    Clopidogrel
    Intervention Type
    Drug
    Intervention Name(s)
    Aspirin
    Other Intervention Name(s)
    Aspirin Protect
    Intervention Description
    Aspirin
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo for APD791
    Other Intervention Name(s)
    Placebo for Temanogrel
    Intervention Description
    Placebo for APD791
    Primary Outcome Measure Information:
    Title
    Pharmacokinetics-Cmax
    Time Frame
    Day1, Day2, Day3, Day4, Day 7
    Title
    Pharmacokinetics-Tmax
    Time Frame
    Day1, Day2, Day3, Day4, Day 7
    Title
    Pharmacodynamics-% inhibition of serotonin-stimulated platelet aggregation
    Time Frame
    Day1, Day2, Day4, Day7, Day 8
    Title
    Pharmacodynamics-change of serotonin-stimulated platelet aggregation
    Time Frame
    Day1, Day4, Day7
    Title
    Pharmacodynamics-% inhibition of TRAP-induced platelet aggregation
    Time Frame
    Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group.
    Secondary Outcome Measure Information:
    Title
    adverse event monitoring
    Time Frame
    up to post-study visit(8day±2)
    Title
    physical examination
    Time Frame
    up to post-study visit(8day±2)
    Title
    vital signs
    Time Frame
    up to post-study visit(8day±2)
    Title
    ECG
    Time Frame
    up to post-study visit(8day±2)
    Title
    laboratory test
    Time Frame
    up to post-study visit(8day±2)

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    45 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: a healthy adult between 20 and 45 years old at the time of visit for screening a person who is able to give written consent a person between 50 and 85 kg at the time of visit for screening a woman who is negative on a serum hCG test at the time of visit and the day before a trial, and who is not nursing, a woman who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, or who had a contraceptive operation no later than 120 days before visit for screening, or who is menopausal, a man who had a contraceptive operation no later than 120 days before visit for screening, or who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, and also agree not to donate sperm a person more than hemoglobin 12 g/dL at the time of screening (a woman more than hemoglobin 11 g/dL) a person whose vital signs were in the normal range at the time of visit for screening, or who is medically determined not to be clinically significant by an investigator Exclusion Criteria: a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer within 90 days from the time of visit for screening a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease, ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or herniotomy) affecting the absorption of a clinical trial drug a person with the medical history of blood coagulation disorder or hemorrhagic diseases, or with clinically significant abnormal findings decided by a investigator on blood coagulation test at the time of screening a woman with the medical history of dysfunctional uterine bleeding within a year from the time of visit for screening a person with the medical history of epilepsy or convulsion a person with the medical history of internal organ transplant a person expected to be hard to complete a clinical trial because of surgery or medical procedures planned within a clinical trial period a person with the medical history of clinically significant new diseases within 30 days from the time of visit for screening according to investigator's decision a person with hypersensitivity reaction to a drug or gelatin, or the medical history of clinically significant hypersensitivity reaction a person with the history of drug abuse, or with a positive reaction to a drug possible to be abused on urine drug screening a person with the medical history of alcohol abuse within two years from the time of visit for screening a person who is a smoker, or with a positive reaction on a urine nicotine test conducted at the time of visit for screening a person who donated whole blood within 60 days or constituents of blood within 30 days, or received a blood transfusion within 30 days from the time of visit for screening a person taking other clinical trial drugs within 90 days from the time of visit for screening a person taking a prescription drug within 30 days, or a contraindicated drug or oriental medicine within 14 days from the time of visit for screening a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test, HIV test, syphilis test) a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or creatinine more than 1.25 times of the reference upper limit(UNL) a person expected to be hard to complete a clinical trial due to physical or mental status according to investigator's medical decision at the time of visit for screening
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Gyunseop Bae, M.D.
    Organizational Affiliation
    Asan Medical Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Dose-escalation, Repeated and Single Oral Dosing Study

    We'll reach out to this number within 24 hrs